TransMedics®

Environmental, Social & Governance

2023 ESG Data Update

About this report

This report includes disclosures that are informed by the Sustainability Accounting Standards Board (SASB) standard for the Medical Equipment & Supplies industry. All financial information is reported in U.S. dollars, and unless otherwise stated, this reporting covers fiscal years 2021, 2022, and 2023, as well as some key activities that occurred in 2024.

Contents

Environmental, Social & Governance (ESG) at TransMedics 4

Transforming Organ Transplantation Therapy Worldwide 5

People 8

Ethics & Compliance 11

Information Security 13

Product Quality & Safety 14

Supply Chain Management 15

Environmental Sustainability 16

Sustainability Accounting Standards Board (SASB) Index 17

References throughout this report to “TransMedics”, “we”, “us”, “our”, or the “Company” refer to TransMedics Group, Inc., unless the context otherwise indicates.

Forward-Looking Statements

This report contains forward-looking statements, which reflects our current views with respect to, among other things, our operations and business plans. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations and financial position, business strategy and plans and our objectives for future operations are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “could,” “target,” “predict,” “seek” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: that we continue to incur losses; our ability to attract and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the Organ Care System (the “OCS”); our ability to expand access to the OCS through the National OCS Program (the “NOP”); our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private payors of benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States, the European Union, and other select jurisdictions worldwide; our ability to adequately respond to FDA, or other competent authorities, follow-up inquiries in a timely manner; performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP to reduce dependence on third party transportation, including by means of the acquisition of fixed-wing aircraft or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; risks related to retaining key Summit employees and risks related to providing logistics and aviation services and owning aircraft; our estimates regarding revenues, expenses and needs for additional financing; and other factors described in our filings with the Securities and Exchange Commission (the “SEC”). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. .The forward-looking statements in this report speak only as of the date of this report. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

TransMedics

Contents

Environmental, Social & Governance (ESG) at TransMedics

Transforming Organ Transplantation Therapy Worldwide

People

Ethics and Compliance

Information Security

Product Quality and Safety

Supply Chain Management

Environmental Sustainability

Sustainability Accounting Standards Board (SASB) Index

Environmental, Social & Governance (ESG) at TransMedics

Our 2023 ESG Data Update supplements the information we provided in our inaugural report, providing key data points and metrics about our ESG performance last year. This report includes disclosures that are informed by the Sustainability Accounting Standards Board (SASB) standard for the Medical Equipment & Supplies industry. All financial information is reported in U.S. dollars, and unless otherwise stated, this reporting covers fiscal years 2021, 2022, and 2023, as well as some key activities that occurred in 2024.

The Nominating and Corporate Governance ("N&CG") Committee of our Board of Directors ("Board") oversees the Company's policies and practices regarding corporate social responsibility and environmental sustainability. At the management level, our ESG program is managed by our Chief Financial Officer and Senior Vice President, General Counsel, and Corporate Secretary, who provide regular reports to the N&CG Committee about the status of ESG matters relevant to our business. For more information about our corporate governance practices, please refer to our most recent proxy statement and the respective charters of our three Board committees:

- Audit Committee
- Compensation Committee
- Nominating and Corporate Governance Committee



2 out of **8** Board members self-identify as gender or ethnically diverse

Contents

Environmental, Social & Governance (ESG) at TransMedics

Transforming Organ Transplantation Therapy Worldwide

People

Ethics and Compliance

Information Security

Product Quality and Safety

Supply Chain Management

Environmental Sustainability

Sustainability Accounting Standards Board (SASB) Index

Transforming Organ Transplantation Therapy Worldwide

TransMedics was founded to expand access to life-saving organ transplant therapy for patients suffering from end-stage organ failure. We aim to help save more patients' lives by becoming the trusted partner to transplant stakeholders worldwide and delivering the highest quality technology, service, and clinical care.

The OCS™ Platform

We believe our Organ Care System ("OCS™") multi-organ platform provides a great opportunity to increase the number of organ transplants worldwide and improve outcomes for transplant patients. The decades-old cold storage standard of care prevents the majority of organs available for donation from being utilized, which significantly limits access to transplant therapy for thousands of patients.

We developed the OCS platform to comprehensively address the major limitations of cold storage, creating a dynamic environment that enables new capabilities for transplantation.

The OCS represents a paradigm shift in organ preservation that allows more organs to remain usable for longer and reach patients in good condition, increasing the utilization of donor organs and improving post-transplant outcomes. To date, the use of the OCS has resulted in more than 5,000 organs transplanted.

The adoption of the OCS has led to meaningful increases in the number of transplants conducted across the country. From 2022 to 2023, heart and liver transplants among U.S. adults increased by approximately 12%. These increases can be ascribed in large part to the adoption of the OCS. Our technology has directly enabled the expansion of the pool of Donation after Circulatory Death ("DCD") donors, which has driven the growth of the overall organ donor pool over the last few years.





Source: OPTN Scientific Registry of Transplant Recipients ("SRTR")

TransMedics

Contents

Environmental, Social & Governance (ESG) at TransMedics

Transforming Organ Transplantation Therapy Worldwide

People

Ethics and Compliance

Information Security

Product Quality and Safety

Supply Chain Management

Environmental Sustainability

Sustainability Accounting Standards Board (SASB) Index

The National OCS Program ("NOP™")

Organ transplantation is a very challenging logistical process. Unlike traditional medical procedures, the process involves two patients, the organ donor and a patient who has a second chance at survival. However, the process of allocating the organ, procuring the organ, and transporting the organ all in a limited timeframe is extremely challenging. Historically, organs could only be transported relatively short distances, meaning that many could not be accepted for procedures.

We believe that increasing the number of available organs will allow organs to be more fairly allocated and distributed to the patients who need them most. To support this objective, we created the NOP, a first of its kind integrated model to maximize organ utilization in the U.S. The NOP provides end-to-end technology and expert clinical services to maximize transplant volume, enhance clinical outcomes, and reduce learning curves on new centers adopting the OCS. The NOP is a turnkey solution for transplant centers that provides outsourced organ retrieval and organ management, creating a more efficient process that reduces logistical barriers associated with transplantation. The NOP also resolves the problem of recovering organs on a regional basis because the OCS platform enables national access to recovered hearts, lungs, and livers.

TransMedics$_{SM}$ Aviation

In 2023, we built upon our commitment to establish a more efficient model for organ transplant therapy by launching TransMedics Aviation, the first integrated national provider of air and ground logistics dedicated exclusively to organ transplants in the U.S. The existing model for organ transplant logistics was insufficient and lacked the scale to support the growing volume and distances that the OCS and NOP enabled. With TransMedics Aviation, we are able to build and manage a national transplant logistics network designed to expand the reach and coverage of the NOP. Transplant centers are now able to select a single solution to access the benefits of the OCS platform, the NOP clinical service, and the NOP logistics service. Our goal is to manage the entire end-to-end process of donor to recipient logistics, which we hope will help remove a critical bottleneck to U.S. transplant volumes.

We established a national digital command and control center at our headquarters to efficiently deploy the TransMedics Aviation fleet from dedicated hubs capable of covering 100% of the U.S. We use a data driven approach to continue to refine the national TransMedics transplant logistical network to maximize coverage and efficiency of the operations.

TransMedics facilitates cost savings for health systems by:

- **Increasing the Number of Transplants**
  Transplantation is the most cost-effective therapy for end-stage organ failure patients. It gives the patient the longest life expectancy and the highest quality of life post-procedure. Therefore, by increasing the number of transplants, the health care system saves significant costs.

- **Reducing Post-Transplant Complications**
  Transplants using the OCS allow patients to leave the ICU and the hospital sooner than with traditional cold storage preserved organs, which also reduces the cost of transplantation.

- **Allowing More Transplants per Day**
  Hospitals have shown that they can now do multiple transplants in a day during normal hospital hours, rather than overnight. This allows for more efficient and cost-effective transplant programs.

- **Reducing Logistics Costs**
  Our dedicated transplant logistics model ensures that organs are moving with the most efficient transportation resources, at the right time, and at the right place. Excess cost related to inefficient aircraft, pilot time-outs, and extra logistics costs are reduced, and our fleet enables multiple organs to be moved with one plane on many occasions.

TransMedics

Contents

Environmental, Social & Governance (ESG) at TransMedics

Transforming Organ Transplantation Therapy Worldwide

People

Ethics and Compliance

Information Security

Product Quality and Safety

Supply Chain Management

Environmental Sustainability

Sustainability Accounting Standards Board (SASB) Index

Corporate Philanthropy in Support of Organ Transplantation

We focus our charitable activity on providing financial support to groups involved across different aspects of organ transplantation. These include patient groups such as the Heart Brothers, which supports heart transplant survivors and advocates. We also contribute to annual transplantation fundraising events such as Transplant Rocks, which supports the Cleveland Clinic Transplant Patient Assistance Fund. In addition, we support transplant-related fellowships with The International Society for Heart and Lung Transplantation ("ISHLT") Foundation and the American Society of Transplant Surgeons ("ASTS"), as well as learning opportunities coordinated through our NOP program.



R&D

Our research, development, and clinical trial operations function consists of a dedicated clinical trial team that has trial management, data collection, and biostatistics expertise. Through the efforts of this team, TransMedics has conducted many large clinical trials in heart, lung and liver transplantation which focused on several different donor indications. The complete data set from our preclinical and clinical studies led to FDA approval of all three of our devices in the U.S. and has supported the registrations of our systems in the E.U. and around the world. In 2023, we continued to invest in the following clinical trial and R&D activities:

- Developing the next generation of the OCS platform
- Expanding the body of clinical evidence supporting the use of the OCS platform through pre-market clinical trials, post-market registries, and scientific publications
- Improving incrementally the technology and manufacturing efficiency of our current platform
- Conducting research to investigate new clinical applications and uses for the OCS platform

TransMedics has conducted many large clinical trials in heart, lung and liver transplantation which focused on several different donor indications.



TransMedics

Contents

Environmental, Social & Governance (ESG) at TransMedics

Transforming Organ Transplantation Therapy Worldwide

People

Ethics and Compliance

Information Security

Product Quality and Safety

Supply Chain Management

Environmental Sustainability

Sustainability Accounting Standards Board (SASB) Index

People

We strive to foster an inclusive, engaging, and safe work environment where employees want to grow their careers. We continually seek exceptionally talented and dedicated people to join our team to help shape both our future and the future of transplant medicine.

We are committed to:

- Attracting top-notch diverse talent for all positions across the organization
- Providing development opportunities to all employees throughout their time at TransMedics
- Paying fair compensation to employees that considers internal equity, market forces, and business needs
- Offering competitive benefits that provide value to employees and their families
- Making TransMedics a great place to work



Contents

Environmental, Social & Governance (ESG) at TransMedics

Transforming Organ Transplantation Therapy Worldwide

People

Ethics and Compliance

Information Security

Product Quality and Safety

Supply Chain Management

Environmental Sustainability

Sustainability Accounting Standards Board (SASB) Index

Recruitment and Talent Attraction

In recent years, our recruitment efforts have been centered on finding talent for the NOP and our engineering, manufacturing, and supply chain operations. Since the launch of our logistics operations in 2023, we are also seeking additional resources in the field of logistics and aviation. We aim to hire people with the right skills, growth mindset, and work ethic to drive business results and help us achieve our goals. To attract top talent in specific locations, we provide relocation benefits to eligible employees whom we request to move in connection with their employment.



Health and Safety

We are committed to maintaining compliance with applicable laws and regulations surrounding the health and safety of our employees and strive to follow best practices in our operations. We require relevant employees to complete workplace safety training before performing any job duties that entail potential health hazards, such as trainings for employees who handle hazardous chemicals and biohazardous materials. We continually strive for zero work-related safety incidents. In 2023, we recorded 3 employee injuries.

Career Development

In 2023, we focused on promoting a culture of learning across TransMedics by rolling out a talent development program designed to enhance the functional and behavioral capabilities of our employees. The program includes courses on fundamental leadership and communication skills for all employees, as well as management courses designed specifically for leaders to coach, develop, and motivate their team members. In 2024, we have made significant investments in technology that will allow us to further expand our development opportunities at all levels and across all functions of our organization.

Talent Development Courses

All Team Members

- Time Management & Priority Setting
- Navigating Beyond Conflict
- Working as a High Performing Team
- Self-Leadership
- Taking the HEAT
- Embracing Change
- Strengthening your Partnerships
- Effective Presentation Skills

Managers and Regional Leaders

- First Time Managers & Leadership Fundamentals
- Coaching for Peak Performance
- Performance Reviews & Goal Setting
- Targeted Selections & Interviewing Skills
- Effective Communication Skills / Behavioral Styles
- Engaging & Retaining Talent
- Situational Leadership

Outside of these programs and courses, all employees receive formal written feedback on their performance at least annually and work with their manager to develop customized career development plans as well as targeted training based on their roles.

Contents

Environmental, Social & Governance (ESG) at TransMedics

Transforming Organ Transplantation Therapy Worldwide

People

Ethics and Compliance

Information Security

Product Quality and Safety

Supply Chain Management

Environmental Sustainability

Sustainability Accounting Standards Board (SASB) Index

Diversity, Equity, and Inclusion

The keystone of our diversity strategy is mutual respect and fostering a sense of belonging – we want everyone to feel welcome and comfortable in our organization and feel that they are supported in growing their careers. Our workforce consists of individuals from countries all over the world, representing many different faiths, languages, backgrounds, and cultures. We believe that our diversity is one of our greatest strengths and a key contributing factor to our success.

We are committed to creating and maintaining an inclusive workplace in which all employees have an opportunity to contribute to the success of the business. This commitment is embedded in our Company policies and human capital management practices. We have also adopted policies to foster a respectful workplace for all employees, such as our sexual harassment policy.

Gender

2023 Total Employees: 547*



*Total number excludes employees assumed in connection with acquisition of Summit Aviation, Inc. in August 2023

Ethnicity



Data above is from TransMedics' 2023 EEO-1 Report. Totals may not add up to 100% due to rounding.

Contents

Environmental, Social & Governance (ESG) at TransMedics

Transforming Organ Transplantation Therapy Worldwide

People

Ethics and Compliance

Information Security

Product Quality and Safety

Supply Chain Management

Environmental Sustainability

Sustainability Accounting Standards Board (SASB) Index

Ethics & Compliance

At TransMedics, we strive to cultivate a culture of integrity and high standards for ethical behavior. Our compliance program is underpinned by our Global Code of Business Conduct and Ethics ("Code"), which reflects our commitment to conducting business in compliance with all applicable laws, rules, and regulations.

Oversight

In June 2023, we appointed a Senior Vice President, General Counsel and Corporate Secretary who is responsible for managing the Company's legal affairs and compliance program. The General Counsel role did not exist at the Company prior to this appointment. Designated members of the Company's management, including the General Counsel, along with the Chief Financial Officer, Sr. Vice President of Human Resources, and Vice President of Global Regulatory Affairs are also tasked with overseeing compliance with the Code. The Audit Committee of the Board oversees the Company's ethics and compliance functions, including matters related to the Code and other procedures covering ethical behavior.

At least annually, management provides the Audit Committee a summary of TransMedics' programs and controls for compliance with legal and regulatory requirements, as well as guidelines and policies governing risk assessment and risk management. Our Code is reviewed by management and the Audit Committee annually and updated as needed. Moreover, we have completed a risk assessment related to compliance and corruption, which the Audit Committee reviews on an annual basis.

Contents

Environmental, Social & Governance (ESG) at TransMedics

Transforming Organ Transplantation Therapy Worldwide

People

Ethics and Compliance

Information Security

Product Quality and Safety

Supply Chain Management

Environmental Sustainability

Sustainability Accounting Standards Board (SASB) Index

Compliance Program Updates and Training

Since our General Counsel's appointment, we have focused on implementing updates to the Code as well as additional targeted training opportunities to raise employee awareness and build competency around specific compliance-related topics. Specifically: (i) in August 2023, we refreshed certain aspects of the Code; (ii) in January 2024, the General Counsel delivered training about the Code and Company's compliance program to functional leaders reporting to the CEO and their respective teams; and (iii) in May 2024, we rolled out a mandatory compliance training program across the entire employee base. In addition to these efforts, all new hires are provided with a copy of the Code and must attest that they understand and acknowledge it during the onboarding process. We continue to evaluate the Code and other key compliance policies and will update such policies as required in 2024.

As of December 2023, TransMedics has not incurred any monetary losses as a result of legal proceedings associated with bribery, corruption, or false marketing claims.

Lobbying and Public Policy

We interact with public policy advisors who engage in lobbying on our behalf, specifically with respect to organ transplant law and policy. In 2023, our corporate lobbying expenditures totaled $117,000.

Conflict Minerals

TransMedics is committed to the responsible sourcing of materials through our global supply chain. In accordance with Section 1502 of the Dodd Frank Wall Street Reform and Consumer Protection Act, reporting companies must determine whether any conflict minerals, such as Tin, Tungsten, Tantalum, or Gold ("3TG") originating in the Democratic Republic of the Congo ("DRC") or certain adjoining countries, are necessary to the functionality or production of their manufactured products. We have established a due diligence process to review our worldwide supply chain for materials that contain 3TG, and we expect all our suppliers to exercise due diligence in their own supply chains and to make their findings available upon request.

As part of our due diligence process, we conducted a reasonable country of origin inquiry ("RCOI") that is designed to determine whether any of the 3TG in our products originate in the DRC or its adjoining countries. This RCOI is based upon conflict minerals-related guidance published by the Organization for Economic Cooperation and Development ("OECD"). In addition, we established a cross-functional team with representatives from our Supply Chain & Operations and Legal functions to monitor supply chain due diligence and reporting. This team met periodically to review and assess due diligence efforts, provide updates to senior management on a case-by-case basis, and recommend actions to strengthen engagement between the Company and our suppliers.

For more information about our conflict minerals due diligence process, please refer to our first specialized disclosure form, which we recently filed with the SEC, as well as our Conflict Minerals Statement.

Contents

Environmental, Social & Governance (ESG) at TransMedics

Transforming Organ Transplantation Therapy Worldwide

People

Ethics and Compliance

Information Security

Product Quality and Safety

Supply Chain Management

Environmental Sustainability

Sustainability Accounting Standards Board (SASB) Index

Information Security

The Audit Committee of the Board oversees the integrity of the Company's information technology ("IT") systems, processes, and data, and reviews and assesses the cybersecurity program with management on a quarterly basis. Additionally, cybersecurity topics are assessed as part of TransMedics' Enterprise Risk Management ("ERM") process.

In 2023, we hired a Chief Information Officer ("CIO") as well as a Senior Director of Information Security, who are rolling out an entirely new security program that provides structure, guidance, and continuous improvement in our cybersecurity practices. The CIO is responsible for strategic alignment of the Company's IT strategies, budgeting, and resource allocation, while the Senior Director of Information Security is responsible for overall cybersecurity strategy, risk management, incident response, security architecture, and cybersecurity awareness.

Last year, we conducted a third-party audit of our cybersecurity capabilities based on the National Institute of Standards and Technology Cybersecurity Framework ("NIST CSF"). The third party outlined several areas of opportunity to improve our cybersecurity program, and the CIO and Senior Director have designed a roadmap to implement the necessary improvements to ensure alignment with the NIST CSF.

In 2024, we plan to implement the following programs and policies:

- Risk Management: Develop a program for ongoing risk assessment and management to identify, prioritize, and mitigate cybersecurity risks
- Asset Management: Establish a program to identify, classify, and manage critical assets and information, ensuring a clear understanding of what needs protection
- Access Control: Implement a program to control and manage access to systems and data, incorporating principles of least privilege and strong authentication
- Continuous Monitoring: Develop a program for continuous monitoring of network activities, systems, and data to detect anomalies and potential security incidents in real time
- Incident Response: Enhance the incident response program with comprehensive, documented procedures for identifying, reporting, and responding to cybersecurity incidents effectively
- Security Awareness and Training: Strengthen the cybersecurity awareness and training program for all employees, including phishing simulation tests and interactive training sessions in order to build a resilient and proactive security culture among employees
- Security Controls: Maintain and enhance critical security controls, including encryption, firewalls, and other protective measures

We believe that we are neither a "covered entity" nor a "business associate" directly under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"). However, HIPAA may affect our interactions with customers who are covered entities or their business associates. Therefore, we strive to follow HIPAA provisions where applicable by implementing appropriate safeguards and controls in order to proactively mitigate privacy risks. We do not store patient-related data on our network or anywhere within the Company premises. We also maintain an information security liability insurance policy to protect against potential financial losses.

Contents

Environmental, Social & Governance (ESG) at TransMedics

Transforming Organ Transplantation Therapy Worldwide

People

Ethics and Compliance

Information Security

Product Quality and Safety

Supply Chain Management

Environmental Sustainability

Sustainability Accounting Standards Board (SASB) Index

Product Quality & Safety

Our Quality Policy outlines our commitment to:

- Providing our customers with OCS and related services of the highest quality
- Operating in accordance with global regulations for medical device companies
- Maintaining the effectiveness of the Quality Management System ("QMS") by meeting and exceeding the established quality objectives

Product quality and safety is overseen by TransMedics' Senior Director, Quality Assurance and the Board receives periodic briefings on the QMS and applicable regulatory requirements. During each of the past four years, TransMedics was not subject to any FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP).

In the U.S., our OCS products are all FDA registered and undergo the FDA Premarket Approval ("PMA") process of scientific and regulatory review to evaluate safety and effectiveness. After approval, we make sure that our products and production processes remain in compliance with FDA and government regulations by evaluating device and manufacturing changes, monitoring complaints and malfunctions, and filing all necessary reports to the FDA and other government agencies worldwide.

To support our compliance efforts, our QMS is certified to the ISO 13485:2016 Medical Device Quality Management System standard and we participate in the Medical Device Single Audit Program ("MDSAP"). In the European Union and other global markets, TransMedics is CE Mark certified in compliance with the E.U. Medical Device Regulation. We also maintain compliance with the FDA's Quality System Regulation ("QSR").

Product quality and patient safety statistics

ZERO

- Product recalls
- Fatalities related to products
- Products on the FDA's MedWatch Safety Alerts database

Quality Training

TransMedics selects and assigns qualified employees to ensure that those performing work affecting product quality possess the appropriate education, skills, and experience to perform their duties. In 2023, TransMedics established new training processes and procedures to raise awareness of the Company's quality objectives among relevant employees and train all employees in accordance with the latest revision of every quality procedure assigned to their job function.

Product Testing and Risk Monitoring

We monitor and measure quality and safety related characteristics across different stages of the product development process to ensure that each product adheres to regulatory requirements. We also conduct product safety risk assessments throughout the lifecycle of our products. We maintain records of product conformance that enable us to identify which personnel and equipment performed certain product testing activities.

We have established a standard operating procedure that lays out the steps needed to remediate product-related issues and conduct corrective actions in the field if necessary. This procedure lays out our policy for issuing advisory notices in advance of corrective actions in accordance with applicable regulatory requirements. We also regularly test our emergency response procedures for product safety incidents.

Contents

Environmental, Social & Governance (ESG) at TransMedics

Transforming Organ Transplantation Therapy Worldwide

People

Ethics and Compliance

Information Security

Product Quality and Safety

Supply Chain Management

Environmental Sustainability

Sustainability Accounting Standards Board (SASB) Index

Supply Chain Management

As part of our commitment to further develop our world class supply chain and manufacturing capabilities to serve our expanding global markets, we restructured our existing supply chain management activities by establishing the Supply Chain & Operations ("SCO") group. Led by the Senior Vice President of Supply Chain and Operations, the SCO is comprised of experienced professionals with proven track records in procurement, integrated planning, and manufacturing. As part of its strategy to improve the Company's supply chain procedures in 2023, the SCO implemented new processes and systems, such as:

- Risk assessments designed to proactively identify and mitigate potential supply chain issues
- Integrated business planning ("IBP") structures intended to ensure the ongoing alignment of supply, demand, and financial objectives
- Managing Daily Improvement ("MDI") processes focused on our manufacturing key performance indicators (Quality, Safety, Productivity, and Output)
- Expanded our Class 7 cleanroom manufacturing space
- Redesigned our manufacturing workflow and implemented a single-piece flow manufacturing process in collaboration with a highly-respected engineering consulting firm

Going forward, the SCO aims to implement new policies and procedures to digitize and improve critical business processes. For example, we plan to upgrade our Enterprise Resource Planning ("ERP") system and invest in a Manufacturing Execution System ("MES") to improve our manufacturing workflows.

Supplier Risk Management and Critical Materials

The SCO is responsible for assessing supplier qualifications, determining supplier suitability, and purchasing materials from approved suppliers. We have classified our suppliers into five tiers that are determined based on risk level and corresponding approval requirements. Our highest risk tier suppliers provide unique materials or services that have the potential to impact product quality and patient health. All our highest risk tier suppliers are either ISO 13485 certified, ISO 9001 certified or GMP registered within their respective countries. Furthermore, our highest risk tier suppliers are audited at least every two years and agree to accommodate unannounced inspections for quality conducted on our behalf by notified bodies.

We seek to maintain sufficient levels of inventory to mitigate against potential supply disruptions and aim to hold approximately 6-12 months' worth of component inventory on hand to support production.

We also have long-standing supply agreements with single-source suppliers of critical components used in the OCS. To ensure adequate inventory of critical supplies, we forecast anticipated materials requirements and demand for our products and then place orders with our suppliers accordingly.

Maintaining Traceability

We assign serial and lot numbers to trace components within our consoles and perfusion sets for quality control purposes. We maintain full traceability of shipments we send to customers and maintain device history records for every unit we distribute, including build date and sterilization date. Our product labels are aligned with the FDA's unique device identification system ("UDI") so that our devices can be adequately identified from manufacturing through distribution to patient use. We have also established standard operating procedures to ensure that our product labeling and packaging activities are verified for compliance with our internal control protocols.

Contents

Environmental, Social & Governance (ESG) at TransMedics

Transforming Organ Transplantation Therapy Worldwide

People

Ethics and Compliance

Information Security

Product Quality and Safety

Supply Chain Management

Environmental Sustainability

Sustainability Accounting Standards Board (SASB) Index

Environmental Sustainability

We aspire to operate as responsible stewards of the environment. We believe doing so is important to the sustainability of our business, as well as beneficial to the planet. We are taking steps to reduce the environmental impact of our products and are gathering key data to better understand the environmental footprint of our operations. With the recent launch of TransMedics Aviation, we considered the environmental impact of the fleet and deployment. Since most transplant missions must utilize a chartered aircraft, we set out to create a highly efficient and environmentally sound transplant aviation operation. First, we chose a unified fleet of new, or nearly new, ultra-light jets. Using a unified fleet of newer model aircraft allows us to use less fuel so we can be environmentally responsible, reduce maintenance costs, and reduce downtime to maximize availability to conduct transplant missions. Second, we dedicated the fleet 100% to transplant missions. This helps to maximize operational efficiency and reduce cost to the transplant centers. Finally, we are focused on maintaining the highest level of air safety for our staff, our clinical users, and the precious donor organs we are caring for. In the coming years, we aim to develop a more complete understanding of our baseline greenhouse gas emissions.

Product Design & Lifecyle Management

Minimizing the amount of power that our consoles consume continues to be a key objective of our product development team, particularly as we strive to extend the range of possible travel distances for organ retrieval using the OCS. As part of our efforts to develop the next generation OCS platform, we are exploring innovative ways to further reduce the footprint of our consoles. We are also working with transplant facilities to reclaim OCS consoles that have reached their end of life to be used again for procedures or utilized for research and training purposes. In 2023, we retrieved 33 consoles from the field to be refurbished and redeployed for further use.

Hazardous Waste

We are committed to complying with all applicable laws and regulations related to the environment. We are registered with the Massachusetts Department of Environmental Protection as a very small quantity generator (“VSQG”) of hazardous waste. The VSQG criteria applies to organizations that produce less than 220 pounds or 27 gallons per month of hazardous waste. Aside from our headquarters facility, none of our NOP sites generate medical or hazardous waste.

In 2023, we retrieved 33 consoles from the field to be refurbished and redeployed for further use.

Contents

Environmental, Social & Governance (ESG) at TransMedics

Transforming Organ Transplantation Therapy Worldwide

People

Ethics and Compliance

Information Security

Product Quality and Safety

Supply Chain Management

Environmental Sustainability

Sustainability Accounting Standards Board (SASB) Index

Sustainability Accounting Standards Board (SASB) Index

The following Index maps TransMedics' disclosures to certain SASB indicators for our industry. Data and information in this Report pertain to efforts in 2021, 2022, and 2023. Disclosures made in accordance with the SASB standards are not necessarily material, within the meaning of the U.S. federal securities laws, to the Company and the inclusion herein of such disclosures should not be considered as an admission of their materiality by the Company.

Disclosure Topic	Accounting / Activity Metric(s)	2023	2022	2021	SASB Code
Affordability & Pricing	Ratio of weighted average rate of net price increases (for all products) to the annual increase in the U.S. Consumer Price Index	0.0x	0.0x	2.1x	HC-MS-240a.1
Affordability & Pricing	Description of how price information for each product is disclosed to customers or to their agents	See "Pricing" section in *Transforming Organ Transplantation Therapy Worldwide* chapter of the 2022 ESG Report, page 13			HC-MS-240a.2
Product Safety	Number of recalls issued, total units recalled	0	0	0	HC-MS-250a.1
Product Safety	List of products listed in the FDA's MedWatch Safety Alerts for Human Medical Products database	0	0	0	HC-MS-250a.2
Product Safety	Number of fatalities related to products as reported in the FDA Manufacturer and User Facility Device Experience database	0	0	0	HC-MS-250a.3
Product Safety	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	0	0	0	HC-MS-250a.4
Ethical Marketing	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	$0	$0	$0	HC-MS-270a.1
Ethical Marketing	Description of code of ethics governing promotion of off-label use of products	See "Ethical Promotion and Advertising of our Products" section in *Ethics & Compliance* chapter of the 2022 ESG Report, page 21			HC-MS-270a.2

Continued on next page

TransMedics

Contents

Environmental, Social & Governance (ESG) at TransMedics

Transforming Organ Transplantation Therapy Worldwide

People

Ethics and Compliance

Information Security

Product Quality and Safety

Supply Chain Management

Environmental Sustainability

Sustainability Accounting Standards Board (SASB) Index

Sustainability Accounting Standards Board (SASB) Index cont.

Disclosure Topic	Accounting / Activity Metric(s)	2023	2022	2021	SASB Code
Product Design & Lifecycle Management	Discussion of process to assess and manage environmental and human health considerations associated with chemicals in products, and meet demand for sustainable products	See "Hazardous Waste" and "Product Design and Lifecycle Management" sections of *Environmental Sustainability* chapter, page 16			HC-MS-410a.1
Product Design & Lifecycle Management	Total amount of products accepted for take-back and reused, recycled, or donated, broken down by: (1) devices and equipment and (2) supplies	See "Product Design and Lifecycle Management" section of *Environmental Sustainability* chapter, page 16			HC-MS-410a.2
Supply Chain Management	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in third-party audit programs for manufacturing and product quality	(11) 100% – The Quality Management System for our headquarters and manufacturing facility is certified to ISO 13485 and participates in the Medical Device Single Audit Program (MDSAP). See *Product Quality & Safety* chapter, page 14 (2) 100% of TransMedics' highest risk tier suppliers participate in third-party certification and audit programs for manufacturing and product quality. See "Supplier Risk Management and Critical Materials" section in the *Supply Chain Management* chapter, page 15			HC-MS-430a.1
Supply Chain Management	Description of efforts to maintain traceability within the distribution chain	See "Maintaining Traceability" section in the *Supply Chain Management* chapter, page 15			HC-MS-430a.2
Supply Chain Management	Description of the management of risks associated with the use of critical materials	See "Supplier Risk Management and Critical Materials" section in the *Supply Chain Management* chapter, page 15			HC-MS-430a.3
Business Ethics	Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption	$0	$0	$0	HC-MS-510a.1
Business Ethics	Description of code of ethics governing interactions with health care professionals	See "Ethical Interactions" section in the *Ethics & Compliance* chapter of the 2022 ESG Report, page 20			HC-MS-510a.2

TransMedics®